Taiho Pharma Canada

Company snapshot

Taiho Pharmaceutical, a subsidiary of Otsuka Holdings Co., Ltd., is an R&D-driven specialty pharma focusing on the three fields of oncology, allergy and immunology, and urology. Its corporate philosophy takes the form of a pledge: “We strive to improve human health and contribute to a society enriched by smiles.” In the field of oncology in particular, Taiho Pharmaceutical is known as a leading co

• 16 active pipeline program(s) linked via ClinicalTrials.gov.
• 16 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Taiho Pharma Canada. Not investment advice.

Recent activity

Latest pipeline, patent, and corporate events for Taiho Pharma Canada.

1. Jun 8, 2026 Clinical update

   TAS0612-101 — Phase 1

2. Jun 8, 2026 Clinical update

   TAS-120-203 — Phase 2

3. Jun 8, 2026 Clinical update

   ASTX727-18 — Phase 1

4. Jun 8, 2026 Clinical update

   ASTX727-17 — Phase 1

5. Jun 8, 2026 Clinical update

   TAS6417-301 — Phase 3

View all clinical trial activity →

• What is Taiho Pharma Canada?

  Taiho Pharma Netherlands is a pharma organization headquartered in EU. Primary therapeutic focus areas include Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Solid Tumors, Stage IB-IIIA NSCLC Patients with uncommon EGFR M

• Is Taiho Pharma Canada publicly traded?

  Taiho Pharma Canada appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Taiho Pharma Canada develop or market?

  We link 30 drug profile(s) where Taiho Pharma Canada is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/taiho-pharma-netherlands-b-v#company-drugs.

• What are the latest developments for Taiho Pharma Canada?

  In the last 12 months our linked public records show 16 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Taiho Pharma Canada focus on?

  Taiho Pharma Canada focuses on Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS), Chronic Myelomonocytic Leukemia (CMML), Solid Tumors based on our analysis of their pipeline programs and drug development activities.